PharmAla Biotech Holdings, Inc. (TSE:MDMA)
:MDMA
Want to see TSE:MDMA full AI Analyst Report?
MDMA Stock Chart & Stats
C$0.11
-C$0.03(-8.33%)
At close: 4:00 PM EST
C$0.11
-C$0.03(-8.33%)
Day’s Range― - ―
52-Week RangeC$0.09 - C$0.20
Previous CloseN/A
Volume63.47K
Average Volume (3M)208.17K
Market Cap
C$16.33M
Enterprise ValueC$18.40M
Total Cash (Recent Filing)C$564.71K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta0.57
Next Earnings
Jul 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding108,887,215
10 Day Avg. Volume94,242
30 Day Avg. Volume208,173
Financial Highlights & Ratios
PEG Ratio-0.05
Price to Book (P/B)5.47
Price to Sales (P/S)22.20
P/FCF Ratio-12.84
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
GMP-compliant MDMA SupplyA focus on GMP-compliant MDMA positions the company as a regulated supplier to clinical trials and potential prescription markets. This creates durable commercial barriers, aligns with growing demand for regulated psychedelic therapeutics, and supports long-term contract and partnership opportunities.
Positive Revenue TrendConsistent TTM revenue growth demonstrates expanding commercial traction or higher trial supply volumes. Over a 2-6 month horizon, continued top-line expansion supports scaling potential, validating demand for the product offering and providing a foundation to improve unit economics with scale.
Debt-free Balance SheetA zero-debt capital structure reduces fixed financial obligations and lowers bankruptcy risk, giving management flexibility to fund development via equity, partnerships, or grants. This structural strength is valuable for a cash-burning biotech in development and supports investment in trials or manufacturing scale-up.
Bears Say
Negative Gross Profit / Unit EconomicsReversion to negative gross profit indicates product costs exceed revenue, signaling deteriorating unit economics. This is a structural concern: without cost reductions or pricing power, margins cannot support sustainable operations, limiting path to profitability even with revenue growth.
Persistent Negative Cash FlowChronic negative OCF and FCF force reliance on external financing, increasing dilution risk and constraining long-term R&D or manufacturing investment. For a development-stage biotech, persistent cash burn is a structural vulnerability that can shorten runway absent durable revenue or funding commitments.
Large Operating And Net LossesSustained operating and net losses erode shareholders' equity and reduce strategic flexibility. Over months, continued losses can necessitate frequent capital raises, impair management's ability to invest in commercialization, and heighten execution risk if key trials or partnerships are delayed.
PharmAla Biotech Holdings, Inc. News
MDMA FAQ
What was PharmAla Biotech Holdings, Inc.’s price range in the past 12 months?
PharmAla Biotech Holdings, Inc. lowest stock price was C$0.09 and its highest was C$0.20 in the past 12 months.
What is PharmAla Biotech Holdings, Inc.’s market cap?
PharmAla Biotech Holdings, Inc.’s market cap is C$16.33M.
When is PharmAla Biotech Holdings, Inc.’s upcoming earnings report date?
PharmAla Biotech Holdings, Inc.’s upcoming earnings report date is Jul 24, 2026 which is in 42 days.
How were PharmAla Biotech Holdings, Inc.’s earnings last quarter?
PharmAla Biotech Holdings, Inc. released its earnings results on Apr 21, 2026. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.
Is PharmAla Biotech Holdings, Inc. overvalued?
According to Wall Street analysts PharmAla Biotech Holdings, Inc.’s price is currently Overvalued.
Does PharmAla Biotech Holdings, Inc. pay dividends?
PharmAla Biotech Holdings, Inc. does not currently pay dividends.
What is PharmAla Biotech Holdings, Inc.’s EPS estimate?
PharmAla Biotech Holdings, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmAla Biotech Holdings, Inc. have?
PharmAla Biotech Holdings, Inc. has 108,887,215 shares outstanding.
What happened to PharmAla Biotech Holdings, Inc.’s price movement after its last earnings report?
PharmAla Biotech Holdings, Inc. reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.226%.
Which hedge fund is a major shareholder of PharmAla Biotech Holdings, Inc.?
Currently, no hedge funds are holding shares in TSE:MDMA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmAla Biotech Holdings, Inc.
Pharmala Biotech Holdings Inc., operating as PharmAla, concentrates its efforts on the research, manufacturing, and bringing to market of active pharmaceutical ingredients (APIs) within the substituted methylenedioxy-phenethylamine (MDXX) class. The company's offerings further extend to various MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB) and 3,4-Methylenedioxy-N-ethylamphetamine (MDEA/MDE), in addition to prepared formulations of these MDXX substances. The enterprise maintains its primary corporate offices in Vancouver, Canada.
Technical Analysis
COSCIENS Biopharma
―
Aptose Biosciences
―
―
PreveCeutical Medical
―
PharmaTher Holdings Ltd
―
Options Prices
Currently, No data available
---